Correlates of immune protection in HIV-1 infection: what we know, what we don't know, what we should know.
about
Few and far between: how HIV may be evading antibody avidityThe Global HIV/AIDS Vaccine Enterprise: scientific strategic planThe failed HIV Merck vaccine study: a step back or a launching point for future vaccine development?Immunization with hepatitis C virus-like particles results in control of hepatitis C virus infection in chimpanzeesDeveloping an HIV vaccine: the role of efficacy studies in nonhuman primatesStandardization of cytokine flow cytometry assaysAn alternative and effective HIV vaccination approach based on inhibition of antigen presentation attenuators in dendritic cells.HIV/AIDS vaccines for Africa: scientific opportunities, challenges and strategiesViewing transplantation immunology through today's lens: new models, new imaging, and new insights.Genetic correlates influencing immunopathogenesis of HIV infectionMicrobicides: a new hope for HIV preventionHIV vaccine development: strategies for preclinical and clinical investigationVaccination-induced noncytolytic effects in the acute phase of SHIV infectionStructure-based stabilization of HIV-1 gp120 enhances humoral immune responses to the induced co-receptor binding siteBiodegradable polymeric microsphere-based vaccines and their applications in infectious diseasesRestoring function in exhausted CD8 T cells during chronic viral infectionComparison of OX40 ligand and CD70 in the promotion of CD4+ T cell responsesPriming immunization with DNA augments immunogenicity of recombinant adenoviral vectors for both HIV-1 specific antibody and T-cell responsesAntigen load and viral sequence diversification determine the functional profile of HIV-1-specific CD8+ T cellsHIV nonprogressors preferentially maintain highly functional HIV-specific CD8+ T cellsCTL epitope distribution patterns in the Gag and Nef proteins of HIV-1 from subtype A infected subjects in Kenya: use of multiple peptide sets increases the detectable breadth of the CTL response.HIV-1 Tat-based vaccines: an overview and perspectives in the field of HIV/AIDS vaccine development.Evolutionary dynamics of HIV at multiple spatial and temporal scales.Human immunodeficiency virus vaccine trialsStatistical approaches to analyzing HIV-1 neutralizing antibody assay dataVACUTAINER CPT and Ficoll density gradient separation perform equivalently in maintaining the quality and function of PBMC from HIV seropositive blood samples.HLA Alleles Associated with Delayed Progression to AIDS Contribute Strongly to the Initial CD8(+) T Cell Response against HIV-1.DNA encoding an HIV-1 Gag/human lysosome-associated membrane protein-1 chimera elicits a broad cellular and humoral immune response in Rhesus macaques.Loss of receptor on tuberculin-reactive T-cells marks active pulmonary tuberculosisAbundance of early functional HIV-specific CD8+ T cells does not predict AIDS-free survival time.Anti-HIV-1 response elicited in rabbits by anti-idiotype monoclonal antibodies mimicking the CD4-binding siteHost HLA B*allele-associated multi-clade Gag T-cell recognition correlates with slow HIV-1 disease progression in antiretroviral therapy-naïve Ugandans.Analysis of Mycobacterium tuberculosis-specific CD8 T-cells in patients with active tuberculosis and in individuals with latent infection.The cat and mouse of HIV-1 antibody escape.Distribution, persistence, and efficacy of adoptively transferred central and effector memory-derived autologous simian immunodeficiency virus-specific CD8+ T cell clones in rhesus macaques during acute infection.A mathematical method for extracting cell secretion rate from affinity biosensors continuously monitoring cell activity.Interference of retroviral envelope with vaccine-induced CD8+ T cell responses is relieved by co-administration of cytokine-encoding vectors.Characterization of T-cell responses in macaques immunized with a single dose of HIV DNA vaccineInsertion of vaccinia virus C7L host range gene into NYVAC-B genome potentiates immune responses against HIV-1 antigensFrequent associations between CTL and T-Helper epitopes in HIV-1 genomes and implications for multi-epitope vaccine designs
P2860
Q21090507-B56C779F-CCA2-493A-A24B-068ECC45D8AAQ21563445-90F701F0-67BC-466D-B83D-0EB0F4014215Q24652185-96513415-B93E-49BC-94CF-34C6A172070EQ24685256-D271D1FA-FDBF-411C-8335-FC85B725E9A7Q24792383-ED83C6D6-2423-44F8-8BC9-03789B871F4CQ24811983-B679D2B1-D427-4D4A-BC18-4E6E644C52CFQ25256583-742E8499-65D8-4162-B68E-7D2A89F4ED66Q26799624-63EE0F2F-D6E2-4E67-B9C8-A6A7BEE55248Q26824352-01E9F45C-A0BF-4C39-A0AB-4E7F73B09856Q26827459-427CDDD6-92F9-42CA-83C8-98D7F1E80000Q27022779-8094C907-5A11-4458-AFEA-28546B2AC261Q27025917-F7CBCBFC-D625-44FE-BEFC-39D0304BC7BBQ27313589-640D566B-0E80-49A1-8856-4C1C13283EE0Q27316899-03718FCF-02C0-4D4A-B7C2-2E2BA957455EQ28087409-AA31901A-060E-42DD-ABE0-CDC2595CD066Q28289222-6553CFFE-6C35-4A46-95AB-E9ECA2B4BF58Q28507643-E7DD99AF-1A9A-40AA-AB77-64486492EE8DQ28749120-CA7B2DD3-65A4-47C8-9066-F62D89C6E810Q28754733-0541ABD2-37DE-47B2-B38D-6BE2D80F0BDEQ29616205-09011128-C744-4066-A910-1D7B6151C661Q30353953-29435EE4-BCD6-4E45-872C-48CF1FC901DFQ30381447-EE3BF2DC-1919-4986-8E10-0E4CDA37477FQ30416280-434AB37E-5104-4123-8245-B08F65A3B1A2Q30424366-61EF7495-F44D-4FC9-A987-D032511BF810Q30784057-EF415AE0-05B7-4DC8-8941-F3EE93174959Q33244711-7B21677D-5376-467A-B65E-A7553E895385Q33262230-DFA9BF57-C172-404C-A2E9-FB3E280A8D0DQ33268303-870848E9-016C-41B2-BF80-DD3A9BDC5379Q33294711-54613129-15E6-4A09-9718-08F3F3ED91CEQ33354070-E399D652-4D01-408C-B0F4-E15314125D38Q33377024-8522BBDC-5E2A-4D1C-980C-4A6EEA569C8DQ33399724-33577FA8-91B8-4A33-A532-E3E6598E9323Q33444815-0CFFC4A5-3FEF-42E3-86A7-DABECA6D32CDQ33504607-7629C088-B307-45A5-8BD7-C19E4CE9C44CQ33554940-7D1178FB-BB96-4C77-91BC-1958D20CD23DQ33561202-B61CBAE2-EFEB-4734-BE6D-D8E9683C35A8Q33613835-FA30953C-E75A-4C0C-B3E7-0B24B956D37BQ33614476-9568EB43-1B0F-4A22-BDEA-087B47B1B730Q33627613-1DCD8AB1-BEFB-442A-A9E7-4140C9C1955DQ33652911-3BD87DB5-D1EC-4F5E-ABEF-AB3B6A0D3335
P2860
Correlates of immune protection in HIV-1 infection: what we know, what we don't know, what we should know.
description
2004 nî lūn-bûn
@nan
2004年の論文
@ja
2004年論文
@yue
2004年論文
@zh-hant
2004年論文
@zh-hk
2004年論文
@zh-mo
2004年論文
@zh-tw
2004年论文
@wuu
2004年论文
@zh
2004年论文
@zh-cn
name
Correlates of immune protectio ...... n't know, what we should know.
@ast
Correlates of immune protectio ...... n't know, what we should know.
@en
type
label
Correlates of immune protectio ...... n't know, what we should know.
@ast
Correlates of immune protectio ...... n't know, what we should know.
@en
prefLabel
Correlates of immune protectio ...... n't know, what we should know.
@ast
Correlates of immune protectio ...... n't know, what we should know.
@en
P2860
P356
P1433
P1476
Correlates of immune protectio ...... n't know, what we should know.
@en
P2093
Richard A Koup
P2860
P2888
P304
P356
10.1038/NM0804-806
P407
P577
2004-08-01T00:00:00Z